Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial*

Severe cases of COVID-19 pneumonia can lead to acute respiratory distress syndrome (ARDS). Release of interleukin (IL)-33, an epithelial-derived alarmin, and IL-33/ST2 pathway activation are linked with ARDS development in other viral infections. IL-22, a cytokine that modulates innate immunity thro...

Descripción completa

Detalles Bibliográficos
Autores principales: Waters, Michael, McKinnell, James A., Kalil, Andre C., Martin, Greg S., Buchman, Timothy G., Theess, Wiebke, Yang, Xiaoying, Lekkerkerker, Annemarie N., Staton, Tracy, Rosenberger, Carrie M., Pappu, Rajita, Wang, Yehong, Zhang, Wenhui, Brooks, Logan, Cheung, Dorothy, Galanter, Joshua, Chen, Hubert, Mohan, Divya, Peck, Melicent C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749945/
https://www.ncbi.nlm.nih.gov/pubmed/36519984
http://dx.doi.org/10.1097/CCM.0000000000005716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749945/
https://www.ncbi.nlm.nih.gov/pubmed/36519984
http://dx.doi.org/10.1097/CCM.0000000000005716

Ejemplares similares